Jenburkt Pharmaceuticals carries a disclosed and audited record: seven years of clean opinions, zero debt, and a decade of cumulative profit that has funded steady dividends. Three things sit on the margin, a ₹16.45 crore regulatory demand pending at the Supreme Court since 2013, a persistent gap between reported profit and cash generation, and promoter remuneration with minimum-payout guarantees approved by shareholders.
Key findings
- A ₹16.45 crore NPPA demand, twice quashed, awaits a Supreme Court hearing
Minor- The NPPA demand of ₹16.45 crore was quashed by the Bombay High Court on 8 August 2013 and 26 September 2013, and the NPPA's SLP has been pending at the Supreme Court since. The company is legally advised the demand is not likely to crystallize and has made no provision. Separately, a GST show cause notice for ITC disallowance demands ₹57.61 Lacs, of which ₹5.76 Lacs was deposited and an appeal filed. - Operating cash flow consistently trails profit, covering 58% of EBITDA over ten years
Minor- Cumulative CFO of ₹153 crore covered 0.58x of cumulative EBITDA of ₹263 crore over the ten-year period ending FY2026. In FY2024, CFO was ₹8.12 crore against PAT of ₹25.98 crore, a CFO/PAT ratio of 0.31x, while FY2026 improved to ₹26.52 crore against ₹34.74 crore, a ratio of 0.76x. The company bought back 176,078 equity shares at a cost of ₹11.42 crore during FY2022-23, funded from free reserves. - Promoter remuneration carries minimum-payout guarantees, and a single insider-trading violation was penalised
Minor- Shri Ashish U. Bhuta's total remuneration rose from ₹173.91 lacs in FY2019-20 to ₹267.09 lacs in FY2025-26. The FY2025-26 AGM notice states that profits available for managerial remuneration were inadequate for the proposed remuneration of Shri Dilip H. Bhuta, and the resolution includes a minimum-remuneration clause for 1 April 2027 to 31 March 2030. A promoter-group member inadvertently sold shares during a trading-window closure in FY2023-24; the company levied a penalty of ₹10,000. - Revenue recognition was a Key Audit Matter in FY2022, and Sri Lanka export collections face headwinds
Minor- The auditor identified revenue recognition under Ind AS 115 as a Key Audit Matter in FY2021-22, verifying samples of local sales, exports, and credit/debit notes. The Board reported in FY2024-25 that Sri Lanka's economic situation, currency fluctuations, import restrictions, and lower demand, impacted export business. Trade receivables as at 31 March 2026 were secured by Bank LC of ₹558.07 lac and Bank Guarantee of ₹184.01 lac. - Key Audit Matters identified in every year from FY2020 through FY2026
Clean- The statutory auditor issued an unqualified opinion on the standalone financial statements for every year from FY2020 through FY2026. Two Key Audit Matters-revenue recognition and purchase accounting-were identified in each of those years. The CARO reports for FY2026 through FY2022 each state that no undisputed statutory dues were in arrears for more than six months. - The statutory auditor has served a normal two-term tenure with partner rotation
Clean- M/s. D. R. Mehta & Associates has been the statutory auditor since 31 July 2017, re-appointed for a second five-year term from 29 July 2022 to the 42nd AGM in 2027. The signing partner changed from Ashok Dhirajlal Mehta in FY2021-22 to Vikram Dhirajlal Mehta from FY2022-23 through FY2025-26. The cost auditor casual vacancy arising from the proprietor's death in FY2022-23 was filled by appointing M/s. Kirit Mehta & Co. effective 1 December 2022.
What to watch
- Supreme Court hearing. The NPPA's SLP for ₹16.45 crore was last listed on 5 June 2024 and posted for four weeks, not yet relisted as of the FY2025-26 Annual Report.
- Auditor term expiry. D. R. Mehta & Associates' second five-year term expires at the conclusion of the 42nd AGM in 2027.
- Director re-appointment. Shri Dilip H. Bhuta's re-appointment as Whole Time Director and CFO for five years from 1 April 2027, with remuneration of ₹108.00 lacs per annum, is subject to shareholder approval at the ensuing AGM.
Bottom line: This is a conservatively run, debt-free company whose audit record is clean and whose legal exposures are disclosed and contested. The character of the risk is slow-burning rather than acute: cash conversion has been thin for a decade, promoter pay is structurally protected against profit dips, and a legacy regulatory demand sits in judicial limbo. Watch the Supreme Court listing and the CST decision for closure on the two outstanding demands.